In June, 23andMe released the MUTYH-Associated Polyposis Genetic Health Risk report* to eligible customers who have opted into receiving this report. This report looks for 2 variants (Y179C and G396D) in the MUTYH gene.
Available now, is an on-demand walkthrough of the MUTYH-Associated Polyposis report. Sample reports for the different possible outcomes are located under the reports tab on our site. By watching this recording, you will learn about our Genetic Health Risk reports, get an overview and walkthrough of the MUTYH-Associated Polyposis report, and learn about resources available for healthcare professionals.
This report-walkthrough is intended for healthcare professionals.
Dr. Ewing is a Medical Science Liaison on the Medical Affairs team at 23andMe and a licensed-certified genetic counselor. As a medical science liaison, Dr. Ewing works with healthcare professionals to help them better understand and navigate the 23andMe health reports so they are equipped to confidently answer their patients’ questions about the content provided within the reports.
*The 23andMe PGS test uses qualitative genotyping to detect select clinically relevant variants in the genomic DNA of adults from saliva for the purpose of reporting and interpreting genetic health risks, including the 23andMe PGS Genetic Health Risk Report for MUTYH-Associated Polyposis. Your ethnicity may affect the relevance of each report and how your genetic health risk results are interpreted. The test is not intended to diagnose any disease and does not describe a person’s overall risk of developing any type of cancer. It is not intended to tell you anything about your current state of health, or to be used to make medical decisions, including whether or not you should take a medication, how much of a medication you should take, or determine any treatments. Warnings & Limitations: The 23andMe PGS Genetic Health Risk Report for MUTYH-Associated Polyposis is indicated for reporting the Y179C and G396D variants in the MUTYH gene and an increased risk for colorectal cancer. The two variants included in this report are most common in people of Northern European descent. This report does not include variants in other genes linked to hereditary cancers and the absence of variants included in this report does not rule out the presence of other genetic variants that may impact cancer risk. The PGS test is not a substitute for visits to a healthcare professional for recommended screenings or appropriate follow-up. Results should be confirmed in a clinical setting before taking any medical action.